

MO HealthNet Managed Care (Medicaid)

<https://provider.healthybluemo.com>

Provider Services: 1-833-405-9086



Healthy Blue

Provider Newsletter

May 2021



Want to receive
the *Provider Newsletter* via email?



Click [here](#) to provide/update your email address.

Table of Contents

**COVID-19 information from
Healthy Blue** Page 2

**Continuing medical
education/continuing
education unit opportunities** Page 2

**Updates to the AIM Specialty
Health Musculoskeletal
Program Clinical
Appropriateness Guidelines** Page 2

**Metabolic monitoring
and diabetes screening
measures for those on
antipsychotics medications** Page 3

BMO-NL-0036-21

Healthy Blue is a Medicaid product offered by Missouri Care, Inc., a MO HealthNet Managed Care health plan contracting with the Missouri Department of Social Services. Healthy Blue is administered statewide by Missouri Care, Inc. and administered in the Kansas City service region by Missouri Care, Inc. in cooperation with Blue Cross and Blue Shield of Kansas City. Missouri Care, Inc. and Blue Cross and Blue Shield of Kansas City are both independent licensees of the Blue Cross and Blue Shield Association.



COVID-19 information from Healthy Blue

Healthy Blue is closely monitoring COVID-19 developments and how the novel coronavirus will impact our customers and provider partners. Our clinical team is actively monitoring external queries and reports from the Centers for Disease Control and Prevention (CDC) to help us determine what action is necessary on our part.

For additional information, reference the COVID-19 Updates page on our [website](#).

Continuing medical education/ continuing education unit opportunities

We offer webinars on a variety of topics, including medical coding, claims issues, quality measures, healthcare and more. Each live webinar may offer both continuing medical education (CME)/continuing education unit credit for attendees. On-demand recordings are also available (with CME credit) for your convenience.

Sign up for a session [online](#) today!

BMO-NL-0964-21

Updates to the AIM Specialty Health Musculoskeletal Program *Clinical Appropriateness Guidelines*

Effective for dates of service on and after September 12, 2021, several updates apply to the AIM Specialty Health®* (AIM) Musculoskeletal Program: *Joint Surgery and Spine Surgery Clinical Appropriateness Guidelines*. Part of the AIM guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.



Read more online.

* AIM Specialty Health is an independent company providing some utilization review services on behalf of Healthy Blue.

BMO-NL-0022-21



Metabolic monitoring and diabetes screening measures for those on antipsychotics medications

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

The Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) HEDIS® measure evaluates the percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing.

Antipsychotic medications can increase a child's risk for developing health concerns, including metabolic health complications. The goal of this measure is for members to have metabolic monitoring by having both a blood glucose test (glucose or HbA1c) and LDL-C testing annually.

Record your efforts:

- Glucose test or HbA1c test and LDL-C cholesterol test as identified by claim/encounter
- Document results in the member's medical record

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

The Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) HEDIS measure evaluates members 18 to 64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, and who were dispensed an antipsychotic medication and had a diabetic screening test during the measurement year.

Diabetes screening is important for anyone with schizophrenia or bipolar disorder. The added risk associated with antipsychotic medications contributes to the need to screen people with schizophrenia for diabetes annually.



Record your efforts:

- Glucose test or HbA1c test as identified by claim/encounter
- Document results in the member's medical record

Helpful tips:

- Educate patients and their caregivers on the importance of completing blood work annually.
- If your practice uses electronic medical records (EMRs), have flags or reminders set in the system to alert when a patient is due for screenings.
- Draw labs in your office, if available, or refer members to a participating lab for screenings.
- Follow up on laboratory test results and document in your chart.
- Share EMR data with Healthy Blue to capture all coded elements.

Other available resources:

- *Clinical Practice Guidelines* are available on our [provider website](#).
- For *The Quality Measures Desktop Reference for Medicaid Providers and HEDIS Benchmarks and Coding Guidelines for Quality Care*, contact Healthy Blue Provider Services.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

BMO-NL-0018-21